CoreCap Advisors’s NovoCure NVCR Stock Holding History

CoreCap Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-210	Closed	-$3.74K	–	3082
2025 Q1	$3.74K	Buy	+210	New	+$4.77K	﹤0.01%	2177
2022 Q3	–	Sell	-2	Closed	–	–	1552
2022 Q2	$0	Buy	+2	New	+$151	﹤0.01%	2228

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CoreCap Advisors's NVCR Position: Q2 2025 in Review

CoreCap Advisors sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 210 shares — an estimated $3.74K sold.

CoreCap Advisors first reported a position in NVCR in Q2 2022 and held it in 2 quarters. The position peaked at $3.74K in Q1 2025. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

CoreCap Advisors reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 210 NovoCure shares in Q2 2025, an estimated $3.74K.
CoreCap Advisors first reported a position in NovoCure in Q2 2022 and held it in 2 quarters.
CoreCap Advisors's NovoCure position peaked at $3.74K in Q1 2025.
242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.